A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells

Author:

Stary Georg1,Olive Andrew1,Radovic-Moreno Aleksandar F.23,Gondek David1,Alvarez David1,Basto Pamela A.23,Perro Mario1,Vrbanac Vladimir D.4,Tager Andrew M.4,Shi Jinjun5,Yethon Jeremy A.6,Farokhzad Omid C.57,Langer Robert23,Starnbach Michael N.1,von Andrian Ulrich H.18

Affiliation:

1. Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA.

2. Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA.

3. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

4. Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

5. Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.

6. Sanofi Pasteur, Cambridge, MA 02139, USA.

7. King Abdulaziz University, Jeddah, Saudi Arabia.

8. Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Abstract

The right combination for protection Despite its prevalence, no vaccine exists to protect against infection with the sexually transmitted bacterium Chlamydia trachomatis . Stary et al. now report on one potential vaccine candidate (see the Perspective by Brunham). Vaccinating with an ultraviolet light-inactivated C. trachomatis linked to adjuvant-containing charged nanoparticles protected female conventional and humanized mice against C. trachomatis infection. The vaccine conferred protection only when delivered through mucosal routes. Protection relied on targeting the bacteria to a particular population of immunogenic dendritic cells and inducing memory T cells that resided in the female genital tract. Science , this issue 10.1126/science.aaa8205 ; see also p. 1322

Funder

NIH

MGH

MIT

Harvard University

arvard Innovation Award from Sanofi Pasteur

David Koch Prostate Cancer Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3